Company Overview
Business Highlights
Financial Highlights
Company Strategy
Q&A
Mission

Make Human and Nature Healthier through Biotechnology
GenScript Biotech (the Cell Therapy Segment)

- Introduced Custom Protein and Antibody Service
- Established research and production center in Nanjing, China
- Launched Legend Biotech (the Cell Therapy Segment)
- Established subsidiary in Japan
- Global headcount reached 1,000
- KPCB / TBIG Healthcare investment
- Launched the Bestzyme (Biotech industrial synthetic biology) product segment
- GenScript Biotech listed in HKEX (Stock code:1548)

- New Nanjing research and production facility opened
- Selected as the sole business entity to participate in the Synthetic Yeast Genome Sc2.0 Project
- Introduced Custom Protein and Antibody Service
- Established research and production center in Nanjing, China
- CRO Leadership award
- Global headcount reached 1,000
- Life Science CRO business achieved 17 years of consecutive growth
- BCMA Program received IND clearance in US and China
- BCMA Program progressing smoothly in both US & China
- Biologics CDMO segment officially established
- BCMA program received Orphan Drug Designation (FDA) & PRIME Designation (EMA)
- Global headcount reached over 2900

- Legend and Janssen entered into collaboration on BCMA program
- CFDA accepted the IND application by Legend
- Acquired 100% of the issued shares of CustomArray
- CFDA accepted the IND application by Legend
- Acquired 100% of the issued shares of CustomArray
- Acquired 100% of the issued shares of CustomArray
- Acquired 100% of the issued shares of CustomArray
- Acquired 100% of the issued shares of CustomArray
- Launched the Bestzyme (Biotech industrial synthetic biology) product segment
- GenScript Biotech listed in HKEX (Stock code:1548)
- Life Science CRO business achieved 17 years of consecutive growth
- BCMA Program received IND clearance in US and China
- BCMA Program progressing smoothly in both US & China
- Biologics CDMO segment officially established
- BCMA program received Orphan Drug Designation (FDA) & PRIME Designation (EMA)
- Global headcount reached over 2900

- Legend and Janssen entered into collaboration on BCMA program
- CFDA accepted the IND application by Legend
- Acquired 100% of the issued shares of CustomArray
- CFDA accepted the IND application by Legend
- Acquired 100% of the issued shares of CustomArray
- Acquired 100% of the issued shares of CustomArray
- Acquired 100% of the issued shares of CustomArray
- Acquired 100% of the issued shares of CustomArray
- Launched the Bestzyme (Biotech industrial synthetic biology) product segment
- GenScript Biotech listed in HKEX (Stock code:1548)
- Life Science CRO business achieved 17 years of consecutive growth
- BCMA Program received IND clearance in US and China
- BCMA Program progressing smoothly in both US & China
- Biologics CDMO segment officially established
- BCMA program received Orphan Drug Designation (FDA) & PRIME Designation (EMA)
- Global headcount reached over 2900

- Legend and Janssen entered into collaboration on BCMA program
- CFDA accepted the IND application by Legend
- Acquired 100% of the issued shares of CustomArray
- CFDA accepted the IND application by Legend
- Acquired 100% of the issued shares of CustomArray
- Acquired 100% of the issued shares of CustomArray
- Acquired 100% of the issued shares of CustomArray
- Acquired 100% of the issued shares of CustomArray
- Launched the Bestzyme (Biotech industrial synthetic biology) product segment
- GenScript Biotech listed in HKEX (Stock code:1548)
- Life Science CRO business achieved 17 years of consecutive growth
- BCMA Program received IND clearance in US and China
- BCMA Program progressing smoothly in both US & China
- Biologics CDMO segment officially established
- BCMA program received Orphan Drug Designation (FDA) & PRIME Designation (EMA)
- Global headcount reached over 2900
Business Blueprint – Incubating the Future

New Area of Business Development Generating Higher Return

Core Business Generating Cash Flow For Future Development

GenScript Proprietary Technologies

Cell Therapy
Industrial Synthetic Biology Products
Life Sciences Research and Application Services and Products
Gene Synthesis
Company Overview

Global Presence
- New Jersey - USA
- Nanjing - China
- Amsterdam - Netherland
- Dublin - Ireland
- Tokyo - Japan

Diversified Customer Base
- 110K+ customers globally including global pharmaceutical and biotech companies, colleges and universities, research institutes, government organizations and distributors in over 160 countries;

Strong IP Position
- Strong IPs and know-how proprietary technology in the area of synthetic biology;
- 100+ granted patents and 250+ patent application;¹

Well Trained Employees
- 2,900+ employees globally;¹
- Over 72% of employees hold Bachelor & above degrees;¹
- Over 34% of employees hold Master & above degrees;¹

¹ As of June 30th, 2019
Major Achievements

2019 Major Achievements

- Life Science CRO business achieved **17 years** of consecutive growth;
- Gene Synthesis remained **No.1 provider globally**, market share expanded to **28+%** worldwide¹
- Industrial Synthetic Biology Products achieved 50% of growth in revenue, new production facility expanded manufactory capacity and improved operational efficiency
- Biologics CDMO signed **5 CMC** projects during the **1st year** of operation
- Biologics CDMO R&D facility enabling projects into **IND stage**²
- BCMA program received **Orphan Drug Designation** from FDA and **PRIME Designation** from EMA;
- BCMA program entitled to **2nd and 3rd milestone** payments of US$25M and US$30M³

---

² As of July 11th 2019
³ As of July 28th 2019
Strategic Business Positioning

Life Science CRO
Continuously Being the Global Leader in Gene Synthesis Services Market

Biologics CDMO
Becoming an Emerging Leader of CDMO Service provider

Industrial Synthetic Biology Products
Make the best Enzyme products to improve the quality of life and maintain a better nature environment

Gene Synthesis Technology

Cell Therapy
Accelerating the science and delivering what's next
One Stop Life Science CRO

Life Science Services
- Largest gene synthesis provider;
- Comprehensive R&D services: gene synthesis, oligo synthesis, DNA sequencing, protein production, peptide synthesis and antibody development;

Life Science Products
- Prepacked, readily available and off-the-shelf products;
- Reagents, equipment, consumables and other biotech tools serving all aspects of life science;
- Innovative and ground-breaking catalogue products, such as eLab series, Magbeads series, etc.

Continuously Enhanced CRO Core R&D Capabilities
- Automatic production line;
- Enrich Magbeads series;
- Next generation synthetic biology technologies
Global No.1 Gene Synthesis Provider

One Out of Every Four Synthetic Genes Comes from Genscript

Largest Gene Synthesis Provider
- >2 M genes delivered\(^1\)
- Successful rate 99.95%\(^1\)
- Over 98.5% on-time delivery\(^1\)
- Record length of >200,000 bp gene synthesized\(^1\)

- CRO Leadership Award
- Long-term partner of iGEM\(^2\)
- Participate in Synthetic Yeast 2.0
- >40,300 Academic Citation\(^4\)

Global Gene Synthesis Outsource Market Size 2018-2025 (Million USD)\(^3\)

1. As of 30th June 2019
2. The International Genetically Engineered Machine
3. Outsourced market data only, Secondary Sources and QYResearch
4. As of 30th June 2019
Life Science CRO – Strategy to Secure Future Growth

Target industrial community to expand customer base and drive business growth with three engines—**R&D, automation and localization**.

**Products & Services Upgrading**
- GMP grade reagents, consumables, & equipment;
- **IND and clinical grade oligo** for gene therapy;
- **Oligo** reagent kits for molecular diagnostics & **Peptide** library for precision medicine;

**Automation**
- **Automation CRO services** to boost per capita revenue of synthesis service;
- **New equipment** enables higher delivery standards & efficiency;

**Global Expansion**
- European & Asia-Pacific Division, new structure supports business development;
- **Localize** Sales & MKT, R&D, and Production, deepen penetration and improve customer experience;
Biologics CDMO Market Potential & Outlook*

**2018**
- **Biologics Manufacture**: $70B
  - CMO Market: $9.7B
  - Preclinical CRO Market: $1.7 B
  - Clinical CRO Market: $8.6 B
- **Biologics R&D**: $44B

**2022**
- **Biologics Manufacture**: $110B
  - CMO Market: $18.9B
  - Preclinical CRO Market: $3.3 B
  - Clinical CRO Market: $16.9 B
- **Biologics R&D**: $63B

*Company Research for illustration only*
Platform Enabling Processes From Target to Market

- **Target Discovery**
  - Target discovery
  - Target validation
  - Project planning and development

- **Lead Generation**
  - Hybridoma development, phage display, humanized transgenic mice
  - SMAB Bispecific antibody
  - HTP screening & characterization

- **Preclinical Development**
  - 360+ Projects
  - Ab humanization
  - Ab affinity maturation
  - Developability assessment

- **Lead Optimization**
  - 180+ Projects
  - Stable cell line development
  - Process development
  - Analytical method development & qualification
  - GMP scale up
  - PD/PK/Safety assessment

- **Clinical & Commercial Manufacture**
  - 7 IND and 3 Clinical Trials
  - GMP compliant manufacture

1. As of 30th June 2019
Advanced SMAB Antibody Platform

Most Natural Bispecific Antibody Platform

Key Advantages:

- Outstanding developability, as good as monoclonal Ab;
- Low immunogenicity, less side effects;
- Flexible format: ≥ 2 targets/epitopes;
- Unique molecular flexibility for precise adjustment of dual target effects

**SMAB**

(Single-domain antibody fused to monoclonal Ab)
# Rapid Growing Biologics CDMO Team

<table>
<thead>
<tr>
<th>Function</th>
<th>Name</th>
<th>Experiences</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEO</td>
<td>Brian Hosung MIN</td>
<td>Samsung Bioepis, AMGEN</td>
</tr>
<tr>
<td>Operation</td>
<td>Daniel Wang</td>
<td>GenScript</td>
</tr>
<tr>
<td>Project Management</td>
<td>Sean Liour</td>
<td>Henlius, Fountain Biopharam</td>
</tr>
<tr>
<td>Bio-Analytics</td>
<td>Heyi Li</td>
<td>Wyeth, Pfizer</td>
</tr>
<tr>
<td>QA</td>
<td>Fredy Chu</td>
<td>Baxter, PharmaEssentia</td>
</tr>
<tr>
<td>Manufacturing</td>
<td>Weifeng Zhang</td>
<td>BMS, Shire</td>
</tr>
</tbody>
</table>

*400+ Staff*  
*180+ Master*  
*30+ PhD & Above*  

*As of August 28, 2019*
Investment in CDMO GMP Facilities to Fuel up Growth

1. From target to preclinical (now operational)
   - Full cycle of Services
   - Antibody Discovery
   - Cell line development, formation and engineering, assay development
   - Preclinical development

2. Enabling Clinical Trials
   - Compliant with GMP regulation in US, CN and EU
   - For clinical I/II

3. Extending to Commercial manufacturing (incl: plasmid & virus)
   - Compliant with GMP regulation in US, CN and EU
   - For Clinical III and Commercial manufacturing
Committed to “Make the Best Enzyme”

Integrated Industry Enzyme Platform

R&D → Manufacturing → Application → Commercial

Advanced R&D Platform
- >80 R&D staff
- Solid IP position
  - 29 granted patents
  - 47 patent applications*

State-of-Art Application Lab
- Five Key application Lab
  - Strain development,
  - Fermentation optimization
  - Extraction & purification
  - Application development
  - Enzyme activity assay

Market-Oriented Business
- Focused on food, feed and starch industries
- Overall production capacity exceeds 150,000 standard tons

* As of June 30th 2019
From Enzyme R&D to Commercial Applications

Cutting-edge enzyme discovery technologies
- Generate new enzyme genes through proprietary gene synthesis platform.

Versatile enzyme expression platforms
- 5 GRAS-grade*, proprietary production strains, one of the highest among enzyme companies

From single products to solution packages
- Deliver top-quality industrial solutions that maximize customers’ business value

Comprehensive R&D capabilities
- Outstanding expertise in all steps of the R&D value chain

*GRAS: Generally Recognized as Safe
Market Potential of Multiple Myeloma

- Total worldwide MM market sales is expected to be ~US$29 billion in 2022E
- US contributed 62% of the total sales, ~US$8.7 billion in 2016
- 230,000 5-year worldwide prevalence
- 1% of worldwide new cancer cases
- 2.1% of all US cancer deaths

Revlimid: 49%
Darzalex: 6%
Other: 2%
Pomalyst: 12%
Kyprolis: 21%
Velcade: 6%

50.7% 5-year survival rate

Legend sdAb-Based Multi-Specific CAR-T Platform

Differentiating LCAR-B38M CAR from Other CARs\(^1,2\)

- Robust screening and engineering
- Better CAR expression and stability
- Easier access to novel and hidden epitopes, especially membrane proximal binders prone to have better efficacy
- More flexibility on multi-specific CAR design
- Smaller size enables more complicated CAR-T design

\( ^1\) Zhao W-H, et al. Presented at 60th ASH Annual Meeting; December 1–4, 2018; San Diego, CA; Abstract 955; \(^2\) Data on File.
Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy

CAR-T/SCM in Development for Patients with Multiple Myeloma

Legend Biotech, Inc. ("Legend Biotech"), a Johnson & Johnson Company, and Janssen Biotech, Inc. ("Janssen"), a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that they have entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Limited ("Legend"), subsidiaries of Legend Biotech Limited, to develop, manufacture and commercialize a chimeric antigen receptor ("CAR") T-cell therapy candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen ("BCMA") and is in the planning phase of clinical studies in the United States for multiple myeloma.

Upfront Payment
$350 million
Q1 2018

First Milestone
$25 million
Dec 2018

Second Milestone
$25 million
Jul 2019

Third Milestone
$30 million
Jul 2019

Legend/Janssen

CARTITUDE-1 (MMY2001)
Phase 1b/2 study in US, Europe, and Israel (NCT03548207)

CARTIFAN-1 (MMY2002)
Phase 2 study in China (NCT03758417)
US & Europe Clinical Trial Updates

Overview
• Phase: 1b/2
• Purpose: Phase 1b to test safety and to determine the dosage of phase 2; Phase 2 to test efficacy

Planned Enrollment
• 60 participants

US Trial Location-Recruiting
• City of Hope – Duarte, CA
• University of Chicago – Chicago, IL
• Barbara Ann Karmanos Cancer Institute – Detroit, MI
• University of Nebraska Medical Center – Omaha, NE
• Mount Sinai Medical Center – New York, NY
• Levine Cancer Institute – Charlotte, NC
• University of Pittsburgh Medical Center – Pittsburgh, PA
• Sarah Cannon Research Institute – Nashville, TN
• Froedtert Memorial, Milwaukee, WI

Worldwide Trial Location-Not yet recruiting
• United States (9 additional sites)
• Belgium (3 sites)
• France (3 sites)
• Israel (2 sites)
• Japan (4 sites)
• Netherlands (3 sites)
• Spain (3 sites)

Current Status
• Patient Treatments triggered off as planned

China Clinical Trial Updates

Overview
• Phase: 2
• Purpose: To test safety and efficacy

Planned Enrollment
• 118 participants

US Trial Location-Recruiting
• City of Hope – Duarte, CA
• University of Chicago – Chicago, IL
• Barbara Ann Karmanos Cancer Institute – Detroit, MI
• University of Nebraska Medical Center – Omaha, NE
• Mount Sinai Medical Center – New York, NY
• Levine Cancer Institute – Charlotte, NC
• University of Pittsburgh Medical Center – Pittsburgh, PA
• Sarah Cannon Research Institute – Nashville, TN
• Froedtert Memorial, Milwaukee, WI

Worldwide Trial Location-Not yet recruiting
• United States (9 additional sites)
• Belgium (3 sites)
• France (3 sites)
• Israel (2 sites)
• Japan (4 sites)
• Netherlands (3 sites)
• Spain (3 sites)

Current Status
• Patient Treatments on going as planned

(1) As of 19 July 2019, (NCT03548207) [Link]
(2) As of 13 August 2019, (NCT03758417) [Link]
## Robust Pipeline of the Next Generation Cell Therapies

<table>
<thead>
<tr>
<th>Program</th>
<th>Target</th>
<th>Status</th>
<th>Pre-clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematologic Malignancies</td>
<td></td>
<td></td>
<td></td>
<td>US / China</td>
<td>US / EU</td>
<td>China</td>
</tr>
<tr>
<td>R/R MM</td>
<td>BCMA</td>
<td></td>
<td>Orphan Drug Designation (FDA)</td>
<td>Ph1b/2</td>
<td>Ph2</td>
<td>US / China</td>
</tr>
<tr>
<td>R/R Multiple Myeloma</td>
<td></td>
<td></td>
<td>PRIME (EMA)</td>
<td>Ph1b/2</td>
<td>Ph2</td>
<td>US / EU</td>
</tr>
<tr>
<td>LCAR-38M (JNJ-4528)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>NHL (DLBCL)</td>
<td>CD19, CD22</td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td>US / EU</td>
</tr>
<tr>
<td>Non-Hodgkin’s Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Diffuse Large B-Cell Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US / EU</td>
</tr>
<tr>
<td>AML</td>
<td>CD33/CLL-1</td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td>US / EU</td>
</tr>
<tr>
<td>Acute Myeloid Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>TCL</td>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US / EU</td>
</tr>
<tr>
<td>T-Cell Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Solid Tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td>US / EU</td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Gastric Cancer</td>
<td>Claudin 18.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US / EU</td>
</tr>
<tr>
<td>Pancreatic Cancer</td>
<td>Claudin 18.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US / EU</td>
</tr>
<tr>
<td>HIV</td>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>China</td>
</tr>
</tbody>
</table>

*IIT (Investigator Initiated Trial)
## Build Up World Class Management Team for Legend

<table>
<thead>
<tr>
<th>Function</th>
<th>US</th>
<th>China</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEO</td>
<td>Yuan Xu - Merck, Gilead, Novartis, Amgen, GSK, Genentech</td>
<td></td>
</tr>
<tr>
<td>CFO</td>
<td>Ying Huang - Bank of America Merrill Lynch, Barclays, Credit Suisse, Wells Fargo, Merck</td>
<td></td>
</tr>
<tr>
<td>R&amp;D</td>
<td>Qiong Wang AstraZeneca, NCI</td>
<td>Frank Fan, Simon Wu GenScript</td>
</tr>
<tr>
<td>Clinical</td>
<td>Syed Rizvi Celgene, Novartis, Merck</td>
<td>Tracy Luo Amgen, AstraZeneca</td>
</tr>
<tr>
<td>Commercial</td>
<td>Steve Gavel Celgene, Millennium, IMS Health, Amgen</td>
<td>Chong Yang Roche, Bayer, Novartis</td>
</tr>
<tr>
<td>Manufacturing</td>
<td>Elizabeth Gosen Eli Lilly, ImClone System</td>
<td>David He Boehringer Ingelheim</td>
</tr>
<tr>
<td>Global Quality</td>
<td>Alan Kick - Celgene, Dendreon, Pfizer, JNJ, Roche</td>
<td></td>
</tr>
<tr>
<td>Global Regulatory</td>
<td>Yuhong Qiu - Novartis, JNJ</td>
<td></td>
</tr>
<tr>
<td>Global Business</td>
<td>Meeta Chatterjee – Merck, Schering-Plough</td>
<td></td>
</tr>
<tr>
<td>Development</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2019 Interim Financial Highlights

<table>
<thead>
<tr>
<th></th>
<th>2019 1H (US$M)</th>
<th>2018 1H (US$M)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>121.9</td>
<td>112.2</td>
<td>8.6%</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>78.9</td>
<td>81.4</td>
<td>(3.1%)</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>64.7%</td>
<td>72.5%</td>
<td></td>
</tr>
<tr>
<td>(Loss)/Profit for the Period</td>
<td>(33.3)</td>
<td>17.6</td>
<td></td>
</tr>
<tr>
<td>Adjusted net (Loss)/Profit¹</td>
<td>(28.0)</td>
<td>21.2</td>
<td></td>
</tr>
<tr>
<td>R&amp;D</td>
<td>62.8</td>
<td>27.9</td>
<td>125.1%</td>
</tr>
<tr>
<td>Capital Expenditure</td>
<td>52.3</td>
<td>45.8</td>
<td>14.2%</td>
</tr>
<tr>
<td>Cash Position²</td>
<td>504.7</td>
<td>577.3</td>
<td>(12.6%)</td>
</tr>
</tbody>
</table>

1. Net profit excluding share base payment expenses
2. Cash Position: Financial assets at fair value through profit or loss + Pledged short term deposits + Time deposits + Cash and cash equivalents

- **Strong Growth of Non-Cell Therapy segments**
  - Revenue achieved a YoY growth of **23.7%** to US$ 101.2M
  - Gross Profit achieved a YoY growth of **14.1%** to US$ 58.2M

- **Significant increase in R&D activities to fuel future business growth**;
  - Cell Therapy R&D increased by **181%** to $51.6M
  - Non-Cell Therapy segments R&D investment maintained ~**10%** of total revenue

- **Continue to maintain strong cash position**
  - Group cash position maintained at US$ 504.7M
Life Science CRO

17 Years of Consecutive Growth

Revenue Growth 20%+
- Successful commercial operation that focuses on synthetic biology industry
- Zhenjiang production facility fully operational
- Improved commercial operations including
  - establishment of European and Asia-Pacific division to support regional strategy
  - more active marketing strategy
  - launched or improved user-friendly online services and platforms

Gross Profit rate maintained at 65%+
- Gross profit increased by 14%
- Expand our customer base to industry customers
- Utilize automation equipment to improve efficiency

3-Year Revenue (US$ M)¹

<table>
<thead>
<tr>
<th>Year</th>
<th>2017 1H</th>
<th>2018 1H</th>
<th>2019 1H</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>54.0</td>
<td>67.3</td>
<td>81.1</td>
</tr>
</tbody>
</table>

3-Year Gross Profit (US$ M)¹

<table>
<thead>
<tr>
<th>Year</th>
<th>2017 1H</th>
<th>2018 1H</th>
<th>2019 1H</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross Profit</td>
<td>38.9</td>
<td>46.4</td>
<td>52.9</td>
</tr>
</tbody>
</table>

¹ 2017 1H Management accounts for illustration only
Biologics CDMO

Unfolding its Potentials

✓ Achieving 27%+ revenue growth
  - 5 CMC projects signed
  - 3 year sales CAGR is at 103%\(^1\)
  - Marketing promotion in both China and U.S. market;
  - Expanded capacity in Gene and cell therapy CDMO services
  - Out-license and collaboration deals of SMAB platform
  - Successful delivery of ongoing projects.

✓ Sustainable Investment for Long-term Growth
  - Invested in GMP facility to meet market demand
  - Invested in our talent pool for fast growth

---

1. 2017 1H Management accounts for illustration only
2. Cash Position=Financial assets at fair value through profit or loss + Pledged short-term deposits + Time deposits+ Cash and cash equivalents
Industrial Synthetic Biology Products

Picking Up its Momentum

✓ Achieving 50%+ revenue growth
  • Focusing on key accounts business development
  • Providing customized service to strategic accounts in strain development, process development and new enzymes products development;
  • Continuous optimization of new production facilities
  • Strong product development and optimization on key products such as amylase, pullulanase and phytase

✓ Both gross profit and gross profit margin increased significantly
  • Gross profit increased by 120%
  • Gross profit margin increased to 20.4%
Cell Therapy

Collaborative Efforts Drive Progress

2-Year Revenue (US$ M)

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (US$ M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018 1H</td>
<td>30.4</td>
</tr>
<tr>
<td>2019 1H</td>
<td>20.7</td>
</tr>
</tbody>
</table>

2-Year R&D Investment (US$ M)

<table>
<thead>
<tr>
<th>Year</th>
<th>R&amp;D Investment (US$ M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018 1H</td>
<td>18.3</td>
</tr>
<tr>
<td>2019 1H</td>
<td>51.6</td>
</tr>
</tbody>
</table>

- **Sustainable revenue contribution from Janssen collaboration**
  - The revenue was mainly attributable to the collaboration with Janssen.

- **Significant investment on Cell therapy R&D activities to accelerate clinical process**
  - US/China Clinical trials R&D expenses
  - New pipeline development R&D expenses
  - Cell Therapy R&D increased by 181% to $51.6M
Enhanced R&D Investment Driving Sustainable Growth

Overall 125.1% of growth in R&D Investment
- US$62.8M in R&D, **125.1%** YoY growth;
- 4-year R&D Investment CAGR is at **85%**;

82.3% of Concentration on Cell therapy R&D
- US$51.6M, **182.0%** YoY growth
- Enabled BCMA program clinical trials progressed smoothly in both US and China
- Development of new cell therapy pipeline, unfolding their potentials

10% of Revenue committed to Non-Cell Therapy segments R&D;
- Development of nova life science CRO services and products
- Optimization of industry enzyme products
- Development of CDMO platform

Prioritized R&D Investment, Foundational to Strategy(US$ M)
Capital Expenditure Analysis in 2019 1H

- **Invest in Lab equipment (~41%)**
  - CRO High throughput and automation;
  - Biologics drug development lab equipment
  - Cell Therapy GMP facility equipment

- **Invest in Infrastructures (~50%)**
  - GMP facilities readiness for Clinical trial both in US and China;
  - Biological R&D center construction & GMP facility build up;
  - Back office construction

- **Invest in land use right for cell therapy GMP facilities (~9%)**
  - Cell therapy GMP land use right in Zhengjiang

---

1. Management accounts. Data derive from MD&A. Capital expenditures = the expenditure incurred in purchasing intangible assets, namely software, patents and license + the expenditure incurred in purchasing property, plant and equipment and construction in process and freehold land.

<table>
<thead>
<tr>
<th>Year</th>
<th>Capital Expenditure 2019 1H (US$ M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017 1H</td>
<td>15.2</td>
</tr>
<tr>
<td>2018 1H</td>
<td>45.8</td>
</tr>
<tr>
<td>2019 1H</td>
<td>52.3</td>
</tr>
</tbody>
</table>
Company Strategy

Life Science CRO

- Implement localization strategy to support global expansion
- Automation to boost CRO efficiency
- Higher industry standard

Biologics CDMO

- Scale up GMP capacity to meet market demand
- Becoming leading Gene and Cell Therapy CDMO service provider
Company Strategy

Cell Therapy

- BCMA program last line commercialization
- Initiate BCMA program early line clinical trials
- Becoming global leading biopharma

Industrial Synthetic Biology Products

- Focus on key accounts
- Production capacity optimization
- R&D & application integration
Content

Company Overview
Business Highlights
Financial Highlights
Company Strategy

Q&A
Thanks

GenScript Biotech Corporation

Make Humans and Nature Healthier through Biotechnology

For More Information:  https://www.genscript.com/

IR Contact E-mail:  IR@genscript.com